Navigation Links
PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis
Date:9/10/2009

rders due to a nonsense mutation. Restoring functional CFTR protein may enable ataluren to address the underlying cause of nmCF and change the course of the disease. Currently available therapies for CF focus only on the alleviation of symptoms.

"We are excited to expand the ataluren registration program to include nmCF, an area of significant unmet medical need," said Langdon Miller, M.D., Chief Medical Officer of PTC Therapeutics. "We are hopeful that this Phase 3 trial together with our ongoing studies in nmDMD/BMD, will add to a growing body of data demonstrating ataluren's potential for treatment of patients with nonsense mutation genetic disorders."

About Cystic Fibrosis (CF)

CF is a life-threatening genetic disease that causes serious lung infections and digestive complications. According to the Cystic Fibrosis Foundation, CF affects approximately 30,000 adults and children in the United States and nearly 70,000 people worldwide. Genetic testing is required to confirm a complete diagnosis and to determine if a patient's disease is caused by a nonsense mutation. It is estimated that nonsense mutations are the cause of CF in 10 percent of patients in the United States and Europe and over 50 percent of patients in Israel. Available treatments for CF are designed to alleviate symptoms rather than correct the underlying cause of the disease. These treatments include chest physical therapy to clear thick mucus from the lungs, antibiotics to treat lung infections, and a mucus-thinning drug designed to reduce the number of lung infections and improve lung function. In addition, the majority of cystic fibrosis patients take pancreatic enzyme supplements to assist with food absorption in digestion. More information regarding CF is available through the Cystic Fibrosis Foundation (www.cff.org).

About Atal
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... SAN FRANCISCO , July 29, 2015 /PRNewswire/ ... trialling mobile molecular testing for applications in food ... Ubiquitome,s hand-held, battery powered real-time PCR device, the ... the farm right through to the supermarket shelf ... world. This includes involvement in animal disease control ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... announced its GHS Label Guide . To align chemical container labeling with ... guide includes explanations of label components, an example of an accurate label, and ...
(Date:7/29/2015)... 2015  Pfenex Inc. (NYSE MKT: PFNX) announced today ... released on Thursday, August 13, 2015, before the open ... will host a conference call to discuss the financial ... outlining the financial results and business update will be ... call 1-866-376-8058 (US) or 1-412-542-4131 (international) and reference Pfenex ...
(Date:7/29/2015)... /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: ... to announce that the final design specifications of ... Prototypes for industrial and regulatory testing will now ... CE mark clearance to market the injector in ... (Photo: http://photos.prnewswire.com/prnh/20150729/248373 )  The ...
Breaking Biology Technology:AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2Brady Announces a New GHS Label Guide 2Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 3RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 4RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 5
... CAMBRIDGE, Mass., Oct. 1 Idenix Pharmaceuticals, Inc. (Nasdaq: ... discovery and development of drugs for the treatment of ... IDX184, the company,s lead hepatitis C development program, have ... of the American Association for the Study of Liver ...
... , Enerkem,s future biofuels plant ... , MONTREAL, Oct. 1 /PRNewswire/ - Enerkem, a leading waste-to-biofuels ... of a community energy initiative that will heat a Strathcona ... its process employed at its Edmonton waste-to-biofuels plant. , The ...
... QUEBEC CITY, Oct. 1 /PRNewswire-FirstCall/ - Medicago Inc. ... highly effective and affordable vaccines based on proprietary ... that it has initiated a Phase I human ... ("H5N1 vaccine"). Enrolment is ongoing and vaccination has ...
Cached Biology Technology:Idenix Announces Data Presentations at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) 2Idenix Announces Data Presentations at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) 3Enerkem Announces Unique Community Energy Project 2Medicago begins human clinical testing with its avian flu pandemic vaccine 2
(Date:7/7/2015)... Calif. , July 7, 2015  Based ... market, Frost & Sullivan recognizes Credence ID, LLC ... Entrepreneurial Company of the Year Award. Credence ... to aid in its mission of offering enrollment ... populations globally. As Credence ID was formed by ...
(Date:7/2/2015)... , June 25, 2015 ... addition of the "Next Generation Biometrics Market by ... 2020" report to their offering. The ... Billion by 2020, at a CAGR of 17.9% between ... the leading application for the market. Safran SA ...
(Date:6/30/2015)... , June 30, 2015 Genisphere ... as CEO to help further develop Genisphere,s therapeutics capabilities ... partnering experience, having spent much of the last 25 ... Amgen, Baxter Bioscience, and Johnson & Johnson. Tom started ... Technology and Biotech Corporate Finance. He graduated from Dartmouth ...
Breaking Biology News(10 mins):Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3
... 19, 2011) When researchers discovered the primary genetic defect ... up a new realm of research into treatment and a ... to clone the defective gene and study its effects in ... Chapel Hill have developed a technique for observing the defects ...
... presumably not lead to a permanent El Nio state ... drawn by an international team of researchers after it ... The growth rings of these fossils indicate that there ... during the last prolonged interglacial phase of the Earth,s ...
... a bidirectional relation between schizophrenia and epilepsy. The study ... the International League Against Epilepsy (ILAE), reports that patients ... develop schizophrenia and those with schizophrenia were close to ... Prior clinical studies have shown a prevalence of psychosis ...
Cached Biology News:The cellular intricacies of cystic fibrosis 250-million-year-old clam shells provide indications of future of El Nino phenomenon 2Study finds bidirectional relationship between schizophrenia and epilepsy 2
... Ciphergen's ProteinChip arrays have been ... from biological samples. A variety of ... of proteins according to their unique ... different spots, allowing side-by-side sample comparison, ...
... have been developed for affinity capture ... variety of ProteinChip chemical surfaces allow ... their unique biochemical properties. Each chip ... sample comparison, and the chips are ...
... Use this kit to purify genomic DNA from plants ... bead beating in a deep well plate using large ... requires a high velocity plate shaker (available through Mo ... a silica membrane spin filter plate. The DNA is ...
... The DNA Engine instrument is ... Unprecedented thermal uniformity and ... and block-to-block. This rugged ... cycler, it's a platform for new ...
Biology Products: